论文信息 - Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP - 字舞流文

Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP

M. Keating | M. Keating | W. Wierda | W. Wierda | S. Koehrer | Stefan Koehrer

[1] E. L. Luning Prak,et al. The ITP syndrome: pathogenic and clinical diversity. , 2009, Blood.

[2] P. Nurden,et al. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura , 2009, The Lancet.

[3] J. Bussel,et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[4] J. George,et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.

[5] Claire Dearden,et al. Disease-specific complications of chronic lymphocytic leukemia. , 2008, Hematology. American Society of Hematology. Education Program.

[6] Shirley A. Williams,et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. , 2003, Blood.

[7] L. Diehl,et al. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. , 1998, Seminars in oncology.

[8] W. Harrington,et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. , 1951, The Journal of laboratory and clinical medicine.